The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement

Research output: Contribution to journalArticle

Abstract

Background and Objective. In adult patients with acute myeloid leukemia (AML), central nervous system (CNS) involvement is a rare event and treatment has not yet been defined. Because there are no definitive data as to the most appropriate therapeutic approach to CNS leukemia in AML, we retrospectively analyzed a cohort of AML patients with meningeal leukemia in order to increase our knowledge on this particular matter. Methods. Out of 410 patients with de novo AML observed at Our institute from 1986 to 1995, 9 (2.2%) showed CNS leukemia (CNSL) during the follow-up. CNSL was treated as follows: in a first group of 4 patients we combined systemic HD Ara-C 3 g/m2 (every 12 hours by 3-hour infusion, for 6 doses), cranial radiation therapy and intrathecal (IT) methotrexate (MTX); a second group of 4 patients was treated with HD Ara-C, IT MTX without cranial irradiation; HD Ara-C alone was administered in one patient. Results. All patients of the first group and 2 patients of the second who achieved a complete remission (CR) had a median survival of 10 months (range 5-25+) after CNS involvement, while for the non- remitters it was 2 months (range 1-5). The only patient still living underwent allogeneic bone marrow transplantation. Interpretation and Conclusions. The combination treatment of HD Ara-C, IT MTX and cranial irradiation is well tolerated and seems to be an effective therapy for CNSL, presenting a high incidence of neurologic CR that correlates with a longer survival. As expected, the number of AML patients with CNSL was small, due to the fact that CNS in those patients is a rare complication. However, this study provides further information about the therapeutic possibilities in such restricted subsets of AML patients.

Original languageEnglish
Pages (from-to)577-580
Number of pages4
JournalHaematologica
Volume82
Issue number5
Publication statusPublished - Sep 1997

Fingerprint

Acute Myeloid Leukemia
Central Nervous System
Leukemia
Cytarabine
Therapeutics
Methotrexate
Cranial Irradiation
Survival
Homologous Transplantation
Bone Marrow Transplantation
Nervous System
Radiotherapy

Keywords

  • Acute myeloid leukemia
  • CNS involvement
  • Radio-chemotherapy

ASJC Scopus subject areas

  • Hematology

Cite this

The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. / Castagnola, Carlo; Nozza, Andrea; Corso, Alessandro; Bernasconi, Carlo.

In: Haematologica, Vol. 82, No. 5, 09.1997, p. 577-580.

Research output: Contribution to journalArticle

@article{cad12822cbc7425887f8c077cb5e3e1d,
title = "The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement",
abstract = "Background and Objective. In adult patients with acute myeloid leukemia (AML), central nervous system (CNS) involvement is a rare event and treatment has not yet been defined. Because there are no definitive data as to the most appropriate therapeutic approach to CNS leukemia in AML, we retrospectively analyzed a cohort of AML patients with meningeal leukemia in order to increase our knowledge on this particular matter. Methods. Out of 410 patients with de novo AML observed at Our institute from 1986 to 1995, 9 (2.2{\%}) showed CNS leukemia (CNSL) during the follow-up. CNSL was treated as follows: in a first group of 4 patients we combined systemic HD Ara-C 3 g/m2 (every 12 hours by 3-hour infusion, for 6 doses), cranial radiation therapy and intrathecal (IT) methotrexate (MTX); a second group of 4 patients was treated with HD Ara-C, IT MTX without cranial irradiation; HD Ara-C alone was administered in one patient. Results. All patients of the first group and 2 patients of the second who achieved a complete remission (CR) had a median survival of 10 months (range 5-25+) after CNS involvement, while for the non- remitters it was 2 months (range 1-5). The only patient still living underwent allogeneic bone marrow transplantation. Interpretation and Conclusions. The combination treatment of HD Ara-C, IT MTX and cranial irradiation is well tolerated and seems to be an effective therapy for CNSL, presenting a high incidence of neurologic CR that correlates with a longer survival. As expected, the number of AML patients with CNSL was small, due to the fact that CNS in those patients is a rare complication. However, this study provides further information about the therapeutic possibilities in such restricted subsets of AML patients.",
keywords = "Acute myeloid leukemia, CNS involvement, Radio-chemotherapy",
author = "Carlo Castagnola and Andrea Nozza and Alessandro Corso and Carlo Bernasconi",
year = "1997",
month = "9",
language = "English",
volume = "82",
pages = "577--580",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement

AU - Castagnola, Carlo

AU - Nozza, Andrea

AU - Corso, Alessandro

AU - Bernasconi, Carlo

PY - 1997/9

Y1 - 1997/9

N2 - Background and Objective. In adult patients with acute myeloid leukemia (AML), central nervous system (CNS) involvement is a rare event and treatment has not yet been defined. Because there are no definitive data as to the most appropriate therapeutic approach to CNS leukemia in AML, we retrospectively analyzed a cohort of AML patients with meningeal leukemia in order to increase our knowledge on this particular matter. Methods. Out of 410 patients with de novo AML observed at Our institute from 1986 to 1995, 9 (2.2%) showed CNS leukemia (CNSL) during the follow-up. CNSL was treated as follows: in a first group of 4 patients we combined systemic HD Ara-C 3 g/m2 (every 12 hours by 3-hour infusion, for 6 doses), cranial radiation therapy and intrathecal (IT) methotrexate (MTX); a second group of 4 patients was treated with HD Ara-C, IT MTX without cranial irradiation; HD Ara-C alone was administered in one patient. Results. All patients of the first group and 2 patients of the second who achieved a complete remission (CR) had a median survival of 10 months (range 5-25+) after CNS involvement, while for the non- remitters it was 2 months (range 1-5). The only patient still living underwent allogeneic bone marrow transplantation. Interpretation and Conclusions. The combination treatment of HD Ara-C, IT MTX and cranial irradiation is well tolerated and seems to be an effective therapy for CNSL, presenting a high incidence of neurologic CR that correlates with a longer survival. As expected, the number of AML patients with CNSL was small, due to the fact that CNS in those patients is a rare complication. However, this study provides further information about the therapeutic possibilities in such restricted subsets of AML patients.

AB - Background and Objective. In adult patients with acute myeloid leukemia (AML), central nervous system (CNS) involvement is a rare event and treatment has not yet been defined. Because there are no definitive data as to the most appropriate therapeutic approach to CNS leukemia in AML, we retrospectively analyzed a cohort of AML patients with meningeal leukemia in order to increase our knowledge on this particular matter. Methods. Out of 410 patients with de novo AML observed at Our institute from 1986 to 1995, 9 (2.2%) showed CNS leukemia (CNSL) during the follow-up. CNSL was treated as follows: in a first group of 4 patients we combined systemic HD Ara-C 3 g/m2 (every 12 hours by 3-hour infusion, for 6 doses), cranial radiation therapy and intrathecal (IT) methotrexate (MTX); a second group of 4 patients was treated with HD Ara-C, IT MTX without cranial irradiation; HD Ara-C alone was administered in one patient. Results. All patients of the first group and 2 patients of the second who achieved a complete remission (CR) had a median survival of 10 months (range 5-25+) after CNS involvement, while for the non- remitters it was 2 months (range 1-5). The only patient still living underwent allogeneic bone marrow transplantation. Interpretation and Conclusions. The combination treatment of HD Ara-C, IT MTX and cranial irradiation is well tolerated and seems to be an effective therapy for CNSL, presenting a high incidence of neurologic CR that correlates with a longer survival. As expected, the number of AML patients with CNSL was small, due to the fact that CNS in those patients is a rare complication. However, this study provides further information about the therapeutic possibilities in such restricted subsets of AML patients.

KW - Acute myeloid leukemia

KW - CNS involvement

KW - Radio-chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031451599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031451599&partnerID=8YFLogxK

M3 - Article

C2 - 9407724

AN - SCOPUS:0031451599

VL - 82

SP - 577

EP - 580

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -